Skip to main content
Nkarta, Inc. logo

Nkarta, Inc. — Investor Relations & Filings

Ticker · NKTX ISIN · US65487U1088 US Manufacturing
Filings indexed 411 across all filing types
Latest filing 2025-08-12 Interim / Quarterly Rep…
Country US United States of America
Listing US NKTX

About Nkarta, Inc.

https://www.nkartatx.com/

Nkarta, Inc. is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. The company's proprietary technology is designed to engineer NK cells to target and eliminate dysfunctional or diseased cells. Nkarta's primary focus is on developing treatments for B cell-mediated autoimmune diseases, with clinical programs investigating therapies for conditions such as lupus nephritis. The company's platform also has applications in oncology. Nkarta aims to provide accessible cell therapies that can reset a disordered immune system and offer new therapeutic options for patients.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2025
2025-08-12 English
8-K
Regulatory Filings
2025-08-12 English
4
Director's Dealing
2025-06-25 English
3
Director's Dealing
2025-06-25 English
4
Director's Dealing
2025-06-20 English
4
Director's Dealing
2025-06-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.